文献速递肝病消化道出血消化内镜

食管静脉曲张出血的二级预防常不完善:一项纳入3592例患者的全国性人群队列研究

Secondary Prevention of Esophageal Variceal Bleeding Is Often Imperfect: A National, Population-Based Cohort Study of 3592 Patients.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-05-14

该研究利用瑞典人群登记数据,纳入2006至2020年首次食管静脉曲张出血的3592例患者,评估120天内非选择性β受体阻滞剂配药和重复内镜检查的累积发生率及总死亡率。结果显示120天内两者累积发生率均为33%,77%接受任一治疗,全程随访总死亡率65%,后期死亡率改善,接受治疗者生存更好。

要点

  • 120天内非选择性β受体阻滞剂配药和重复内镜的累积发生率均为33%,77%接受任一治疗。
  • 全程随访(中位1.7年)总死亡率为65%,2016-2020年较2006-2010年调整风险比0.80(95%CI 0.71-0.89)。
  • 接受非选择性β受体阻滞剂和重复内镜者总生存更好,调整风险比0.80(95%CI 0.72-0.90)。

核心结论

  • 食管静脉曲张出血的二级预防未广泛开展,许多患者未在合理时间框架内接受指南支持的治疗。
  • 作者认为需要提高临床医生和患者对适当预防策略的认识。

研究设计与样本

  • 基于瑞典人群登记数据的全国性人群队列研究,纳入2006至2020年首次食管静脉曲张出血患者3592例,中位年龄63岁(四分位距54-71岁)。

主要发现

  • 120天内非选择性β受体阻滞剂配药和重复内镜检查的累积发生率均为33%,77%接受任一治疗。
  • 全程随访(中位1.7年)总死亡率为65%。
  • 2016-2020年期间较2006-2010年期间总死亡率改善,调整风险比0.80(95%CI 0.71-0.89)。
  • 接受非选择性β受体阻滞剂和重复内镜检查者较未接受者总生存更好,调整风险比0.80(95%CI 0.72-0.90)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Secondary prevention of esophageal variceal bleeding is important to improve prognosis, but uptake of guidelines is unknown in a real-world setting. Here, we determined the proportion of patients receiving appropriate nonselective beta-blocker treatment and repeat upper endoscopy after a first episode of esophageal variceal bleeding within a reasonable time frame. METHODS: Population-based registers were used to identify all patients with a first episode of esophageal variceal bleeding in Sweden from 2006 to 2020. Crosslinkage between registers was performed to receive information on the cumulative incidence of patients with a dispensation of nonselective beta-blockers and repeat upper endoscopy within 120 days from baseline. Overall mortality was investigated using Cox regression. RESULTS: In total, 3592 patients were identified, with a median age of 63 (interquartile range, 54-71) years. The cumulative incidence of a dispensation of nonselective beta-blockers and a repeat endoscopy within 120 days was 33%. A total of 77% received either of these treatments. Overall mortality was high, with 65% of patients dying after esophageal variceal bleeding during the full follow-up period (median 1.7 years). We observed an improved overall mortality during the later years of the study period (adjusted hazard ratio for the 2016-2020 period compared with the 2006-2010 period, 0.80; 95% confidence interval, 0.71-0.89). Patients with receipt of nonselective beta-blockers and repeat upper endoscopy had better overall survival compared with those without (adjusted hazard ratio, 0.80; 95% confidence interval, 0.72-0.90). CONCLUSIONS: Secondary prevention of esophageal variceal bleeding has not been widely undertaken, with many patients not receiving guideline-supported interventions within a reasonable time frame. This highlights a need to raise awareness on appropriate prevention strategies to clinicians and patients.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Hagström H, Shang Y, Tapper EB, et al. Secondary Prevention of Esophageal Variceal Bleeding Is Often Imperfect: A National, Population-Based Cohort Study of 3592 Patients. Clin Gastroenterol Hepatol. 2023. PMID: 37192714. doi:10.1016/j.cgh.2023.05.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。